Bone metastases in thyroid cancer patients represent an advanced disease state often refractory to conventional treatments. This study scrutinizes the diagnostic and prognostic potential of combining RAI and ^18F-FDG PET/CT uptake patterns from 67 patients treated over a 15-year period. The researchers meticulously classified the patients into three categories based on their bone lesion uptake: those with RAI-positive but PET-negative lesions (RAI+/PET-), those positive on both RAI and PET scans (RAI+/PET+), and those negative on RAI but positive on PET imaging (RAI-/PET+). This stratification forms the backbone of the study’s novel insights.

Intriguingly, the study uncovered that the RAI+/PET+ group dominated the cohort, representing nearly 60% of the patients, while the RAI+/PET- and RAI-/PET+ groups comprised smaller proportions. These uptake patterns correlated profoundly with clinical outcomes, suggesting a biological basis for the metabolic behavior observed through imaging. This nuanced approach challenges previous one-dimensional interpretations of metastatic thyroid cancer progression.

One of the study’s central findings highlights the RAI(+) ratio—the proportion of bone lesions exhibiting RAI uptake—as a powerful determinant of progression-free survival (PFS) and overall survival (OS) within the RAI+/PET+ subgroup. Patients with more than 50% of lesions demonstrating RAI positivity exhibited significantly improved clinical trajectories, with extended median PFS and OS periods compared to those with lower ratios. This suggests that the extent of iodine avidity in bone metastases retains a prognostic gravity even amidst FDG-avidity, a marker traditionally associated with aggressive disease.

Moreover, a pivotal advance in this research comes from the employment of total lesion glycolysis (tTLG), a quantitative PET/CT imaging biomarker that integrates both tumor volume and metabolic activity. tTLG emerged as an independent prognostic factor in multivariate analyses for both PFS and OS, underscoring its valuable role in risk stratification and therapeutic decision-making. The capacity to measure tTLG could revolutionize tailoring patient-specific management strategies in metastatic DTC, optimizing treatment efficacy and surveillance intensity.

Underlying these observations is the suggestion that RAI+/PET+ patients exhibit biological behaviors akin to RAI+/PET- patients rather than RAI-/PET+ cases. This parallels the hypothesis that the dual uptake pattern signifies a phenotype retaining differentiation features amenable to RAI therapy, contrasting with the more dedifferentiated and metabolically active PET-only positive lesions. The identification of this subclassification holds potential to refine risk assessment and personalize targeted interventions.

Histopathological and biochemical variables, including serum thyroglobulin levels and patient age, were also corroborated as significant covariates affecting survival outcomes. These findings resonate with existing literature emphasizing the multifactorial nature of prognosis in advanced thyroid cancer and fortify the need for comprehensive multimodal assessment integrating imaging, laboratory, and clinical parameters.

Notably, the study spans data accrued over 15 years, reflecting a robust longitudinal perspective on therapeutic outcomes in a rare and complex patient subset. All subjects underwent standardized ^131I treatment protocols, allowing for a uniform appraisal of RAI responsiveness in relation to imaging phenotypes. The rigorous methodological design and extended follow-up enhance the credibility and clinical applicability of these insights.

This research underlines the integral value of combining anatomical, functional, and metabolic imaging modalities in illuminating the pathobiology of bone metastatic DTC. Such multiparametric imaging approaches could refine the clinician’s ability to forecast disease trajectory, facilitating early intervention adjustments that may prolong survival and maintain quality of life.

For the medical community, these findings signal the dawn of more precise prognostic tools leveraging uptake patterns beyond conventional staging criteria. This could pave the way for stratifying patients who may benefit from intensified RAI therapy or adjunctive treatments targeting high metabolic activity lesions identified through ^18F-FDG PET/CT.

Furthermore, the study stimulates vital discourse regarding the biological underpinnings dictating differential tracer uptake in metastatic lesions, hinting at evolving tumor heterogeneity during disease progression. Future research elucidating molecular correlates of these imaging phenotypes may unlock novel therapeutic targets aimed at overcoming treatment resistance.

In conclusion, the integration of RAI and ^18F-FDG PET/CT uptake patterns, particularly the quantification of the RAI(+) ratio and tTLG, emerges as a transformative paradigm in prognostic evaluation for DTC patients with bone metastases. The implications for personalized medicine are profound, urging oncologists and nuclear medicine specialists to adopt this dual-imaging strategy to optimize patient outcomes in this challenging clinical scenario.

As advances continue, this study’s insights into the prognostic independence of tTLG and the clinical relevance of RAI uptake ratios herald a promising era of precision oncology in thyroid cancer. The synthesis of imaging biomarkers with clinical parameters will likely redefine therapeutic algorithms, tailoring interventions to the metabolic profile and iodine avidity of metastatic lesions.

Such strides underscore the indispensable role of nuclear imaging innovations in cancer management, enabling more than mere detection but offering deep prognostic and therapeutic guidance. Patients harboring metastatic DTC deserve this precision, which has the potential to inform risk-adapted therapies and ultimately improve longevity and quality of life.

This landmark research not only enriches the scientific comprehension of thyroid cancer metastasis but also charts a clear clinical pathway for enhancing prognostic accuracy and treatment personalization through integrative imaging biomarkers. The convergence of metabolic imaging and clinical oncology thus represents a frontier of hope and improved therapeutic stewardship.

Subject of Research: Clinical outcomes influenced by bone metastasis uptake patterns in differentiated thyroid cancer

Article Title: Clinical outcomes by bone metastasis uptake pattern in differentiated thyroid cancer

Article References:
Wang, G., Feng, F., Huang, S. et al. Clinical outcomes by bone metastasis uptake pattern in differentiated thyroid cancer. BMC Cancer 25, 1617 (2025). https://doi.org/10.1186/s12885-025-15036-5

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15036-5

Thyroid cancers such as anaplastic thyroid cancer (ATC) and poorly differentiated thyroid cancer (PDTC) are characterized by their aggressive nature and poor prognosis, with conventional treatments offering limited survival benefits and an average patient lifespan often measured in months. AIC100’s targeted mechanism seeks to address the critical unmet need in these diseases by leveraging the immune system’s cytotoxic T lymphocytes, reprogrammed to recognize and eradicate ICAM-1 expressing tumor cells. This therapeutic approach not only signifies a novel strategy for thyroid cancers but also expands the potential horizons of CAR T cell technology.

The AIC100 construct represents a third-generation CAR T cell, incorporating enhancements intended to improve efficacy and persistence within the hostile tumor microenvironment of solid cancers. Specifically, AIC100’s CAR molecule binds the ICAM-1 protein, a transmembrane glycoprotein frequently overexpressed in ATC and PDTC cells, facilitating tumor infiltration and cytotoxic activity. Importantly, the CAR T cells co-express somatostatin receptor 2, allowing real-time in vivo tracking using positron emission tomography (PET) imaging, a sophisticated adaptation that enables clinicians to monitor distribution and treatment response non-invasively.

In this multicenter Phase I trial, 24 adult patients with newly diagnosed or relapsed/refractory ATC or PDTC were enrolled, many of whom had exhausted standard-of-care therapies with an average of two prior treatment regimens. The study employed a dose-escalation design exploring three initial dose levels of AIC100 administered after a lymphodepleting chemotherapy regimen, intended to enhance CAR T cell engraftment by reducing host regulatory immune cells. Of these patients, 15 received the investigational therapy, and evaluable data from dose levels two and three revealed encouraging clinical activity.

Specifically, among four ATC patients treated at the higher dose cohorts, the overall objective response rate reached 50%, with one achieving a complete response and another demonstrating a partial response. This level of tumor reduction and durable disease control, sustained up to seven months post-infusion, is unprecedented in this patient population. Moreover, in five PDTC patients, 60% experienced disease stabilization, suggesting both types of thyroid cancer may be amenable to this immunotherapeutic approach.

Safety signals from the trial were favorable, with no dose-limiting toxicities observed at the first three dose levels. Most adverse events comprised mild to moderate cytokine release syndrome (CRS), a common immune activation-related toxicity seen in CAR T therapies, which was manageable and transient. Notably, no cases of immune effector cell-associated neurotoxicity syndrome (ICANS), a frequent and serious complication in CAR T cell treatment, were reported. However, exploration of a fourth, escalated dose revealed the emergence of grade 3 pneumonitis in two patients, underscoring the necessity for careful dose optimization.

The safety profile combined with early efficacy led investigators to select dose level three as the recommended dose for future Phase II trials. These findings provide a compelling proof of concept for the application of CAR T cell therapy in solid tumors, an area historically fraught with challenges due to tumor heterogeneity, immune suppression within the tumor microenvironment, and physical barriers to T cell trafficking.

AIC100’s innovative design, including the somatostatin receptor PET-tracking feature, offers an important tool for understanding CAR T cell kinetics and persistence over time, which are critical parameters linked to long-term therapeutic success. This dual functionality may enable dynamic treatment adjustments and early identification of resistance or relapse, ultimately improving patient outcomes through precision immunotherapy.

Samer Srour, MB ChB, associate professor and principal investigator of the trial, emphasized the transformative potential these results hold. He noted that achieving complete and partial remissions in such an aggressive clinical setting is both a validation of the therapeutic strategy and an impetus for further development. The prospect of durable remissions could shift the current therapeutic landscape and significantly extend survival for patients afflicted with these lethal thyroid cancer subtypes.

This Phase I study was funded by AffyImmune Therapeutics, reflecting a productive academic-industry collaboration crucial for advancing cutting-edge immuno-oncology interventions. As the team prepares for larger-scale investigations, the oncology community eagerly anticipates more robust data on efficacy and long-term safety that could pave the way for regulatory approval and expanded clinical use.

In summary, the promising safety and efficacy profile of AIC100 in this early clinical evaluation signals a new frontier in the treatment of solid tumors, highlighting the potential for tailored CAR T cell therapies to overcome previous barriers and improve outcomes in hard-to-treat thyroid cancers. Further developments in this line of research could bring a much-needed paradigm shift, transforming fatal diagnoses into manageable chronic conditions or potentially curable diseases.

Subject of Research: CAR T cell therapy targeting ICAM-1 in aggressive thyroid cancers
Article Title: Novel CAR T Cell Therapy AIC100 Shows Promising Early Results in Aggressive Thyroid Cancers
News Publication Date: April 29, 2025
Web References:

• https://www.mdanderson.org/treatment-options/car-t-cell-therapy.html
• https://www.mdanderson.org/cancer-types/thyroid-cancer.html
• https://faculty.mdanderson.org/profiles/samer_srour.html
• https://www.abstractsonline.com/pp8/#!/20273/presentation/10430
• https://www.aacr.org/meeting/aacr-annual-meeting-2025/
• https://MDAnderson.org/AACR
  Image Credits: The University of Texas MD Anderson Cancer Center
  Keywords: Cancer treatments, Cell therapies, Thyroid cancer, Cancer patients, T cell responses, Clinical trials, T lymphocytes, Thyroid diseases, Gene targeting, Cellular proteins, Solid tumors, Target proteins, Cancer research, Cancer relapse, Neurological disorders, Tumor cells, Disease control